NEWS & EVENTS 2018-09-27T16:26:10+00:00

NEWS & EVENTS

Please check back here often for updates and news related to the Company’s development and the advancement of its compounds.

Please check the Articles section for related materials and background information on the development of opioid analgesics and opiate addiction treatments.

In Vitro and In Vivo Profile of PPL-101 and PPL-103: Mixed Opioid Partial Agonist Analgesics with Low Abuse Potential.

By | September 27th, 2018|Categories: Uncategorized|

Full Article
Comments Off on In Vitro and In Vivo Profile of PPL-101 and PPL-103: Mixed Opioid Partial Agonist Analgesics with Low Abuse Potential.

Research Declares Phoenix PharmaLabs’ Opioid PPL-103 Safe

By | September 27th, 2018|Categories: Uncategorized|

Full Article
Comments Off on Research Declares Phoenix PharmaLabs’ Opioid PPL-103 Safe

n Vitro and In Vivo Profile of PPL-101 and PPL-103: Mixed Opioid Partial Agonist Analgesics with Low Abuse Potential

By | September 27th, 2018|Categories: Uncategorized|

Full Article
Comments Off on n Vitro and In Vivo Profile of PPL-101 and PPL-103: Mixed Opioid Partial Agonist Analgesics with Low Abuse Potential

Phoenix Pharma Labs Technology Transfer Grant

By | July 30th, 2018|Categories: Uncategorized|

Phoenix PharmaLabs has received a Technology Transfer Grant from the National Institutes of Health to evaluate its lead compound as a potential treatment for cocaine addiction. Dr. Larry Toll, our CTO, was recruited earlier this year by Florida Atlantic University to become the University’s first recruit under the 21st Century World Class Scholars Program established by the state of Florida, and the $250k Grant will be administered jointly with FAU in Boca Raton, Florida. We are ecstatic to be able to conduct this important research!

Original article

Comments Off on Phoenix Pharma Labs Technology Transfer Grant

Pleas to Lawmakers Have Had an Impact

By | January 12th, 2018|Categories: Uncategorized|

Perhaps our pleas to lawmakers have had an impact.

Please contact your local representatives so they can put some pressure to get this bill approved.

The goal of this bill (S. 2260) is to expand, intensify, and coordinate fundamental, translational, and clinical research capabilities of the National Institutes of Health with respect to opioid abuse, the understanding of pain, and the discovery and development of safer and more effective treatments and preventive interventions for pain. ”

This is a 5 year, $5 Billion (with a B) initiative that supports the following:

1. directs the National Institutes of Health to intensify and coordinate fundamental, translational, and clinical research with respect to

(A) the understanding of pain;

(B) the discovery and development of therapies for chronic pain; and

(C) the development of alternatives to opioids for effective pain treatments.

2. Developing improved options and evidence for medication-assisted treatment.

3. Developing improved options and evidence for opioid overdose reversal treatments.

4. The Federal Pain Research Strategy, including research that focuses on—

(A) novel drugs, non-addictive, and non-pharmacological treatments for pain;

(B) screening tools and outcome measures for assessments across the continuum of pain;

(C) national registries, datasets, and research networks;

(D) effective models of care delivery for pain management; and

(E) precision medicine methodology to prevent and treat pain.

5. The components of the Department of Health and Human Services five-point strategy to address the opioid crisis that states: “Providing support for cutting edge research on pain and addiction”.

6. The pain therapy screening program established under section 4.

7. Other elements that the Secretary of Health and Human Services may designate, in consultation with the Director of the National Institutes of Health.

Hopefully we can get enough support to get this bill approved!

https://www.congress.gov/…/115th-cong…/senate-bill/2260/text

Comments Off on Pleas to Lawmakers Have Had an Impact
Load More Posts